Company Encyclopedia
View More
name
PULIKE
603566.SH
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc.
3.157 T
603566.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking155/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.51%C
    • Profit Margin13.02%B
    • Gross Margin61.70%A
  • Growth ScoreC
    • Revenue YoY1.65%C
    • Net Profit YoY41.30%B
    • Total Assets YoY0.00%C
    • Net Assets YoY-2.33%D
  • Cash ScoreC
    • Cash Flow Margin768.31%B
    • OCF YoY1.65%C
  • Operating ScoreD
    • Turnover0.36D
  • Debt ScoreA
    • Gearing Ratio16.60%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Huachuang Securities: In the first three quarters, most vaccine varieties saw year-on-year growth in batch approvals, and pet vaccines continued to maintain a high growth rate

    Huachuang Securities released a research report stating that in the first three quarters of 2023, the batch issuance volume of most vaccine varieties increased year-on-year, especially with outstanding performance in pet vaccines and ruminant vaccines. Despite the pressure of internal competition in the animal husbandry industry, the prices of veterinary raw materials have stabilized and rebounded. Focus on undervalued and resilient targets. Specific data shows significant growth in pig vaccines, poultry vaccines, and pet vaccines, reflecting the positive impact of farming profitability and the launch of new products

    Zhitong·
    SH
    603392
    +0.37%
    SH
    600201
    +3.08%
    SH
    603566
    +0.46%
    Zhitong·
    SH
    603392
    +0.37%
    SH
    600201
    +3.08%
    SH
    603566
    +0.46%

    Huachuang Securities: In August, the growth of vaccines for diarrhea, brucellosis, and feline trivalent was strong, and the raw materials for veterinary drugs are entering a peak season with price increases

    HuaChuang Securities released a research report indicating that since 2025, the prices of veterinary raw materials have stabilized and rebounded, especially for macrolide products, where prices and profits have significantly improved. From January to August, the batch issuance data for vaccines saw a substantial year-on-year increase, with pet vaccines such as rabies vaccine and feline trivalent vaccine growing by 16.8% and 78.9%, respectively. The prices of veterinary raw materials rebounded since late August, with the VPI index rising by approximately 2.1%. The tightening of supply and increased demand have driven price increases, particularly benefiting products like florfenicol as market competition eases

    Zhitong·
    SZ
    300119
    -0.21%
    SH
    600201
    +3.08%
    SZ
    300142
    +0.34%
    Zhitong·
    SZ
    300119
    -0.21%
    SH
    600201
    +3.08%
    SZ
    300142
    +0.34%

    PULIKE: 265 million idle fundraising cash management matures, recovering principal of 821 million with earnings of 3.6653 million

    In August-September 2024, PULIKE Biotechnology Co., Ltd. plans to conduct cash management for temporarily idle raised funds not exceeding 265 million yuan, subject to review and approval. The usage period will be valid for 12 months from the date of approval at the third extraordinary general meeting of shareholders in 2024. On August 22, 2025, the company will fully redeem the idle raised funds under cash management and return them to the designated account

    Zhitong·
    SH
    603566
    +0.46%
    Zhitong·
    SH
    603566
    +0.46%

    Guohai Securities: The "Matthew Effect" in the animal protection industry intensifies, and pet pharmaceuticals and overseas expansion are expected to open up medium to long-term growth space

    Guohai Securities released a research report indicating that the domestic animal health industry is undergoing structural adjustments, with sales growth slowing to 3.7% from 2020 to 2023, and gross profit declining by 3.2%. As pet health awareness increases, pet medical care and overseas expansion will become new growth points. Leading companies are expected to gain larger market shares due to their rich product offerings and investment in research and development. Competition within the industry is intensifying, with frequent price wars, putting pressure on small and medium-sized enterprises

    Zhitong·
    SZ
    300119
    -0.21%
    SH
    688098
    +0.76%
    SZ
    002688
    +0.99%
    Zhitong·
    SZ
    300119
    -0.21%
    SH
    688098
    +0.76%
    SZ
    002688
    +0.99%

    PULIKE issued a profit forecast, expecting a year-on-year increase of 44.70% to 64.98% in net profit attributable to the parent company in the first half of the year

    PULIKE expects that the net profit attributable to the parent company in the first half of 2025 will increase by 44.70% to 64.98% year-on-year, reaching between 107 million and 122 million yuan. The launch of new products such as the live vaccine for pseudorabies in pigs and the adenovirus series five-in-one vaccine for poultry has driven performance growth, and sales of pet-related products continue to grow rapidly. The company optimizes costs and strengthens sales expense control through marketing system reform and lean production management to ensure the achievement of sales targets

    Zhitong·
    SH
    603566
    +0.46%
    Zhitong·
    SH
    603566
    +0.46%
    © 2025 Longbridge｜Disclaimer